446 related articles for article (PubMed ID: 18182975)
21. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
22. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
23. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
[TBL] [Abstract][Full Text] [Related]
24. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
[TBL] [Abstract][Full Text] [Related]
25. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
26. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
27. [HPV vaccine].
Yoshikawa H
Nihon Rinsho; 2008 Oct; 66(10):1957-60. PubMed ID: 18939496
[TBL] [Abstract][Full Text] [Related]
28. [Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline].
Gross G; Gissmann L; Hillemanns P; Ikenberg H; Kaufmann AM; Petry KU; Pfister H; Schneede P; Schneider A; Smola S;
Dtsch Med Wochenschr; 2010 May; 135(21):1083-6. PubMed ID: 20486060
[No Abstract] [Full Text] [Related]
29. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
30. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
31. Screening for cervical cancer: controversy and contention or thoughtful analysis.
Frable WJ
Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
[No Abstract] [Full Text] [Related]
32. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
34. A public health approach to cervical cancer control: considerations of screening and vaccination strategies.
Goldie S
Int J Gynaecol Obstet; 2006 Nov; 94 Suppl 1():S95-105. PubMed ID: 17276172
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
[TBL] [Abstract][Full Text] [Related]
36. Issues in human papillomavirus vaccination in adolescents.
Moscicki AB; Smith JS
J Adolesc Health; 2008 Oct; 43(4 Suppl):S1-4. PubMed ID: 18809142
[No Abstract] [Full Text] [Related]
37. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
38. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
[TBL] [Abstract][Full Text] [Related]
39. Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective.
Farnsworth A
Acta Cytol; 2011; 55(4):307-12. PubMed ID: 21791898
[TBL] [Abstract][Full Text] [Related]
40. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
